Ocugen Posts $84.6M Cash With Runway to 2028; OCU400 Phase 3 Data Due Q1 2027
OCGN is trading near its 52-week low of $0.691 (12% above the low).
Summary
Ocugen ended the third quarter with $84.6 million in cash, equivalents, restricted cash and short-term investments, which management says funds operations into 2028. Q3 operating expenses were $19.7 million, roughly flat with the $19.4 million a year earlier, and the net loss per share narrowed to $(0.01) from $(0.07), helped by a $16.6 million favorable swing in the fair value of the convertible note derivative. The balance sheet now carries $83.1 million of convertible notes and a $17.1 million derivative liability, with stockholders' equity in a $17.7 million deficit. The clinical calendar is the real story: OCU400 Phase 3 liMeliGhT topline data are expected in Q1 2027 ahead of a planned BLA, and OCU410ST Phase 2/3 topline data are expected in Q2 2027. OCU410 dosing has begun in the 240-patient ArMaDa3 Phase 3 GA trial, and the Bahamas LARTA provisional approval for OCU400 could allow patient enrollment as early as year-end. The company also named Jolanda Crombach, formerly of Moderna Netherlands, to run its new Amsterdam affiliate. Q1 2027 OCU400 topline is the binary event that matters.
At the time of this announcement, OCGN was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $252.7M. The 52-week trading range was $0.69 to $2.73. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.